	US 12,458,595 B2
	Thermally stabilized nanoemulsion
Henry J. Smith, Temecula, CA (US)
Filed by Henry J. Smith, Temecula, CA (US)
Filed on Oct. 15, 2018, as Appl. No. 16/350,199.
Prior Publication US 2020/0113828 A1, Apr. 16, 2020
Int. Cl. A61K 39/395 (2006.01); A61K 9/107 (2006.01); A61K 45/06 (2006.01); A61K 47/68 (2017.01); A61K 47/69 (2017.01)

CPC A61K 9/1075 (2013.01) [A61K 45/06 (2013.01); A61K 47/6849 (2017.08); A61K 47/6851 (2017.08); A61K 47/6855 (2017.08); A61K 47/6907 (2017.08)]

6 Claims

1. A thermally stabilized antinuclear antibody-linked dactinomycin nanoemulsion wherein said nanoemulsion is formulated to have a phase transition temperature that is below 37 C and above 8 C; and wherein the nanodroplets comprising said nanoemulsion are uniformly sized to be 50 to 300 nm in diameter and are composed of a) dactinomycin, b) one or more oils, c) one or more phospholipids, d) DSPE-PEG2,000, e) DSPE-PEG2,000-Maleimide, and f) are coated with the Fab fragment of the antinuclear antibody.